WALTHAM, Mass., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company
focused on bioprocessing technology leadership, today announced that it will present at the 35th Annual J.P. Morgan
Healthcare conference being held January 9-12 at the Westin St. Francis in San Francisco. Tony J. Hunt, President and Chief
Executive Officer, will make a formal presentation on Thursday, January 12, at 11:00 a.m. PST.
A live webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited
period of time following the conference event.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of
highly innovative products used to improve the process of manufacturing biologic drugs. Our bioprocessing products are sold to
major life sciences companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. We are
the leading manufacturer of Protein A affinity ligands, a critical component of Protein A resins that are used to separate and
purify monoclonal antibody-based therapeutics. In upstream processes, our XCell™ ATF systems and growth factors are used to
accelerate and increase productivity during the cell culture stage of biologic drug manufacturing. In downstream processes, we
developed and market our innovative line of OPUS® chromatography columns that we deliver pre-packed with our customers’
choice of resin for their bench-scale through clinical production-scale purification needs. With the acquisition of TangenX, we
also manufacture single-use Sius™ TFF cassettes and hardware, used in downstream protein concentration and filtration processes.
Repligen’s corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA, Shrewsbury,
MA, Lund, Sweden and Weingarten, Germany.
This press release may contain forward-looking statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which are not strictly historical statements including, without
limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to
time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any
forward-looking statements, except as required by law.
Contact: Sondra S. Newman Senior Director Investor Relations Repligen Corporation (781) 419-1881 snewman@repligen.com
